No Covid-19 patient in Maharashtra died due to oxygen shortage: Tope

Maharashtra Health Minister Rajesh Tope on Sunday said that no COVID-19 patient died in the state-run hospitals due to the shortage of medical oxygen.

Rajesh Tope
Photo: ANI
Press Trust of India Jalna
2 min read Last Updated : Apr 18 2021 | 7:37 PM IST

Maharashtra Health Minister Rajesh

Tope on Sunday said that no COVID-19 patient died in the state-run hospitals due to the shortage of medical oxygen.

He also said most of the COVID-19 fatalities have occurred due to the delay on part of patients in seeking proper medical treatment.

Tope termed "false" the media reports that the shortage of medical oxygen resulted in the death of COVID-19 patients in some parts of the state.

"I have received reports from (government) hospitals in the state. No COVID-19 patient died due to the shortage of oxygen in these hospitals," he told reporters.

Earlier this week, kin of 10 COVID-19 patients who died at two hospitals in Palghar district neighbouring Mumbai had alleged that a shortage of oxygen led to the deaths.

Civic authorities in Palghar and the management of the medical facilities had denied these allegations.

Tope attributed most COVID-19 fatalities due to late admission in hospitals.

"Especially in rural areas, coronavirus positive patients are being traditionally treated by local doctors," he said.

Tope further said that people showing specific symptoms should get themselves tested for coronavirus without delay and seek medical treatment.

He also appealed to eligible people to get vaccinated for COVID-19.

"There are 4,200 vaccination centres in Maharashtra where eligible people can go and get themselves inoculated," the health minister said.

Tope also appreciated doctors and frontline workers for their efforts and dedication during the pandemic.

Maharashtra, which is the worst-affected state in India, recorded a total of 37,70,707 COVID-19 cases till Saturday while 59,970 patients have died so far, as per the state health department.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Apr 18 2021 | 7:31 PM IST

Next Story